Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Biomedit LLC is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed across 2 distinct art units, indicating some technical concentration within the field. The portfolio involves 3 distinct examiners, meaning that each pending action is being reviewed by a different individual. While the examiners are diverse, the concentration in 2 distinct art units suggests that the technical subject matter is relatively focused within the broader biotechnology and pharmaceuticals area.
DAVID W BERKE-SCHLESSEL is identified as the busiest examiner, although he is responsible for only 1 pending office action. This reflects an even distribution of the 3 pending office actions among the 3 distinct examiners. Practitioners should prepare for 3 different review styles across the 2 distinct art units. The strategy for Biomedit LLC must account for this examiner diversity while navigating the technical requirements of the 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
| ZEMAN, ROBERT A | 1 | 54.3% | +27.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694118 | Methods of Inhibiting Diseases Caused by Respiratory Viruses | ZEMAN, ROBERT A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704175 | PROBIOTIC LACTOBACILLUS STRAIN COMPOSITIONS AND APPLICATIONS THEREFOR INCLUDING FOR LEAKY GUT AND INFLAMMATION | GRASER, JENNIFER E | — |
| 18694118 | Methods of Inhibiting Diseases Caused by Respiratory Viruses | ZEMAN, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1645 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704175 | PROBIOTIC LACTOBACILLUS STRAIN COMPOSITIONS AND APPLICATIONS THEREFOR INCLUDING FOR LEAKY GUT AND INFLAMMATION | GRASER, JENNIFER E | 1645 | §112 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18694118 | Methods of Inhibiting Diseases Caused by Respiratory Viruses | ZEMAN, ROBERT A | 1645 | §103§112Other | Non-Final OA | — | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial